News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QLT Inc. (QLTI) Shows Positive Efficacy Trends From Data in Plug Combinations in Phase II Studies for Glaucoma Using Latanoprost Punctal Plug Delivery System


10/25/2012 9:49:11 AM

VANCOUVER, British Columbia, Oct. 24, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) announced that results from two Phase II clinical studies, PPL GLAU 12 and PPL GLAU 13, demonstrate positive trends (with statistically and clinically significant findings) on the efficacy and safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in subjects with ocular hypertension (OH) and open-angle glaucoma (OAG).

Read at GlobeNewswire

comments powered by Disqus
QLT Inc.
 
 
Glaucoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES